What is Leerink Partnrs’ Forecast for ALNY FY2024 Earnings?

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) – Equities researchers at Leerink Partnrs dropped their FY2024 earnings estimates for shares of Alnylam Pharmaceuticals in a note issued to investors on Tuesday, January 21st. Leerink Partnrs analyst M. Foroohar now anticipates that the biopharmaceutical company will post earnings of ($2.48) per share for the year, down from their prior estimate of ($1.74). The consensus estimate for Alnylam Pharmaceuticals’ current full-year earnings is ($2.24) per share. Leerink Partnrs also issued estimates for Alnylam Pharmaceuticals’ Q4 2024 earnings at ($0.94) EPS, FY2025 earnings at ($2.00) EPS and FY2026 earnings at $0.49 EPS.

Several other equities research analysts have also issued reports on ALNY. Barclays lifted their price objective on Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the company an “overweight” rating in a research note on Friday, November 1st. HC Wainwright reaffirmed a “buy” rating and issued a $400.00 target price on shares of Alnylam Pharmaceuticals in a research note on Monday, January 13th. Cantor Fitzgerald reissued a “neutral” rating and issued a $220.00 price target on shares of Alnylam Pharmaceuticals in a research note on Friday, October 11th. Royal Bank of Canada restated an “outperform” rating and set a $300.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Tuesday. Finally, Bank of America upped their target price on shares of Alnylam Pharmaceuticals from $307.00 to $314.00 and gave the stock a “buy” rating in a research report on Monday, October 14th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and nineteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $298.61.

Alnylam Pharmaceuticals Stock Up 1.2 %

Shares of NASDAQ:ALNY opened at $278.76 on Thursday. The company has a market cap of $35.95 billion, a price-to-earnings ratio of -106.40 and a beta of 0.34. Alnylam Pharmaceuticals has a one year low of $141.98 and a one year high of $304.39. The firm has a fifty day moving average price of $247.13 and a two-hundred day moving average price of $260.26. The company has a debt-to-equity ratio of 31.64, a current ratio of 2.75 and a quick ratio of 2.69.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The firm had revenue of $500.90 million for the quarter, compared to the consensus estimate of $532.91 million. During the same period in the prior year, the firm posted $1.15 EPS. The firm’s revenue was down 33.3% compared to the same quarter last year.

Insider Activity

In other news, CEO Yvonne Greenstreet sold 5,219 shares of the firm’s stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total value of $1,309,864.62. Following the completion of the transaction, the chief executive officer now owns 78,880 shares in the company, valued at $19,797,302.40. This trade represents a 6.21 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Phillip A. Sharp sold 11,250 shares of the company’s stock in a transaction on Thursday, January 23rd. The stock was sold at an average price of $275.00, for a total value of $3,093,750.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 21,372 shares of company stock valued at $5,634,205. Corporate insiders own 1.50% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Dimensional Fund Advisors LP lifted its holdings in shares of Alnylam Pharmaceuticals by 4.3% during the second quarter. Dimensional Fund Advisors LP now owns 266,206 shares of the biopharmaceutical company’s stock valued at $64,702,000 after purchasing an additional 11,027 shares during the last quarter. Amalgamated Bank raised its stake in Alnylam Pharmaceuticals by 3.7% during the second quarter. Amalgamated Bank now owns 8,354 shares of the biopharmaceutical company’s stock valued at $2,030,000 after buying an additional 301 shares during the last quarter. Summit Trail Advisors LLC bought a new stake in Alnylam Pharmaceuticals in the second quarter worth $226,000. Xponance Inc. grew its stake in shares of Alnylam Pharmaceuticals by 7.0% in the second quarter. Xponance Inc. now owns 21,076 shares of the biopharmaceutical company’s stock worth $5,121,000 after acquiring an additional 1,378 shares during the last quarter. Finally, BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp increased its holdings in shares of Alnylam Pharmaceuticals by 61.6% during the second quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 24,217 shares of the biopharmaceutical company’s stock valued at $5,885,000 after acquiring an additional 9,234 shares in the last quarter. 92.97% of the stock is owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.